|
BOSTON, September 29, 2025 – The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of Comirnaty® (Pfizer, BioNTech), Spikevax® (Moderna), mNexspike® (Moderna), and Nuvaxovid® (Novavax) for the prevention of COVID-19, including both the short- and long-term effects of the infection.
The assessment will be publicly discussed during a meeting of the New England CEPAC in June 2026, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report.
ICER’s website provides timelines of key posting dates and public comment periods for this assessment.
“ICER’s long-standing topic selection process prioritizes reviews that are timely, clinically significant, and inform public policy considerations,” said ICER President and CEO Sarah K. Emond, MPP. “There are few health interventions right now that meet these three criteria as well as vaccines for COVID-19. Our transparent, evidence-based process will assess the comparative clinical effectiveness and value of these vaccines and will contribute to the body of evidence needed to inform consequential public health decisions.”
Consistent with ICER’s process for announcing new assessments, we will spend the next five weeks conducting outreach and engaging with targeted stakeholders, including relevant patient groups, manufacturers, and clinical experts. Based on this preliminary cross-stakeholder engagement, ICER will post a Draft Scoping Document which will be available for public comment on or about November 10, 2025 and will provide more detail on ICER’s planned analyses. The documents will be open to public comment for three weeks.
ICER’s Patient Portal and Manufacturer Engagement Guide provide additional guidance for submitting public comments, including suggestions for what types of information may be most useful.
Following the public comment period, a revised scoping document will be posted on or about December 12, 2025.
| 
